Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605491712 | ||
| 003 | CHVBK | ||
| 005 | 20210128100511.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150401xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0722-2 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0722-2 | ||
| 245 | 0 | 0 | |a Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations |h [Elektronische Daten] |c [Ozlem Goksel, Tuncay Goksel, Gursel Cok, Haydar Karakus, Feza Bacakoglu, Erdem Goker, Ruchan Uslu, Munevver Erdinc] |
| 520 | 3 | |a Background: Chemotherapy is one of the main treatments for lung cancer, and in these patients, discontinuation of treatment due to uncontrollable hypersensitivity reactions (HSRs) is an important problem. Aim: To determine the frequency of HSRs during chemotherapy and to review current approaches. Methods: We did a cross sectional study in patients undergoing chemotherapy for lung cancer in a reference chemotherapy unit from January 2012 to January 2013. Patients who developed immediate-HSRs or delayed-HSRs to chemotherapeutics and gave consent were included into study. The effectiveness of a standardised 12-step "rapid drug desensitisation” (RDD) procedure was investigated in patients with immediate-HSRs. Results: In total, 1,099 cycles of chemotherapy were administered to 292 patients in 1year. We observed ten HSRs, during ten cycles in ten patients (~3% of the patients). Two HSRs were delayed-type, eight were immediate-type at grade 1-3. Of those with immediate-type HSR, five patients with grade 2-3, and additional two referred patients with grade 4 HSRs were successfully given their culprit drug in 35 cycles of chemotherapy with 12-step or modified 20-step RDD protocol. Conclusions: HSRs to chemotherapeutics are not so rare. Premedication alone does not prevent such reactions. The results of RDD treatment look promising for continuing treatment with the culprit chemotherapeutic agent. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Lung cancer |2 nationallicence | |
| 690 | 7 | |a Chemotherapeutics |2 nationallicence | |
| 690 | 7 | |a Hypersensitivity |2 nationallicence | |
| 690 | 7 | |a Rapid drug desensitisation |2 nationallicence | |
| 690 | 7 | |a HSR : Hypersensitivity reaction |2 nationallicence | |
| 690 | 7 | |a SIR : Standard infusion reaction |2 nationallicence | |
| 690 | 7 | |a RDD : Rapid drug desensitisation |2 nationallicence | |
| 690 | 7 | |a SPT : Skin prick test |2 nationallicence | |
| 700 | 1 | |a Goksel |D Ozlem |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | |
| 700 | 1 | |a Goksel |D Tuncay |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | |
| 700 | 1 | |a Cok |D Gursel |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | |
| 700 | 1 | |a Karakus |D Haydar |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | |
| 700 | 1 | |a Bacakoglu |D Feza |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | |
| 700 | 1 | |a Goker |D Erdem |u Department of Medical Oncology, Ege University Medical School, Izmir, Turkey |4 aut | |
| 700 | 1 | |a Uslu |D Ruchan |u Department of Medical Oncology, Ege University Medical School, Izmir, Turkey |4 aut | |
| 700 | 1 | |a Erdinc |D Munevver |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 395-404 |x 1341-9625 |q 20:2<395 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0722-2 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0722-2 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Goksel |D Ozlem |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Goksel |D Tuncay |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Cok |D Gursel |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Karakus |D Haydar |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Bacakoglu |D Feza |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Goker |D Erdem |u Department of Medical Oncology, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Uslu |D Ruchan |u Department of Medical Oncology, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Erdinc |D Munevver |u Department of Chest Diseases, Ege University Medical School, Izmir, Turkey |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/2(2015-04-01), 395-404 |x 1341-9625 |q 20:2<395 |1 2015 |2 20 |o 10147 | ||